Andy Chen
Overview
Explore the profile of Andy Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1030
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cui C, Xu Y, Xiong X, Aryal U, Chen A, Chien S, et al.
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39940798
Treating advanced metastatic cancer, particularly with bone metastasis, remains a significant challenge. In previous studies, induced tumor-suppressing (iTS) cells were successfully generated through genetic, chemical, and mechanical interventions. This study...
2.
Khare S, Williamson S, OBarr B, Schachter L, Chen A, Hayes-Lattin B, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Oct;
25(2):e120-e125.
PMID: 39426942
Background: Chimeric antigen receptor T-cell (CAR-T) therapies are available for patients with Non-Hodgkin Lymphoma (NHL); however, their use has been limited in accessibility due to nondisease factors. Patients & Methods:...
3.
Wang T, Ahn K, Shadman M, Kaur M, Ahmed N, Bacher U, et al.
Leukemia
. 2024 May;
38(7):1564-1569.
PMID: 38750138
CD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or bridging therapy can sometimes lead to a complete response...
4.
Xiong X, Huo Q, Li K, Cui C, Chang C, Park C, et al.
Theranostics
. 2024 Feb;
14(4):1430-1449.
PMID: 38389836
Osteosarcoma (OS), a common malignant bone tumor, calls for the investigation of novel treatment strategies. Low-intensity vibration (LIV) presents itself as a promising option, given its potential to enhance bone...
5.
Doan A, Mueller K, Chen A, Rouin G, Daniel B, Lattin J, et al.
Res Sq
. 2023 Nov;
PMID: 37986944
Poor CAR T persistence limits CAR T cell therapies for B cell malignancies and solid tumors. The expression of memory-associated genes such as (protein name TCF1) is linked to response...
6.
Banerjee T, Newman M, Chen A, Maziarz R, Schachter L, Spurgeon S, et al.
Leuk Lymphoma
. 2023 Jun;
64(8):1472-1475.
PMID: 37287113
No abstract available.
7.
Di Napoli Parr M, ONeal E, Zhou S, Williams B, Butler K, Chen A, et al.
Dev Psychol
. 2023 Apr;
59(6):1098-1108.
PMID: 37036665
This investigation examined whether the mode of locomotion matters in how 8-, 10-, 12-, and 14-year-old children ( = 91) judge dynamic affordances in a complex perception-action task with significant...
8.
Minami K, Liu S, Liu Y, Chen A, Wan Q, Na S, et al.
Sci Rep
. 2022 Nov;
12(1):19798.
PMID: 36396712
No abstract available.
9.
Gauthier J, Gazeau N, Hirayama A, Hill J, Wu V, Cearley A, et al.
Blood
. 2022 Apr;
139(26):3722-3731.
PMID: 35439295
CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T cells are novel therapies showing great promise for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL). Single-arm studies showed significant...
10.
Kim M, Banerjee T, Chen A, Danilov A, MacKinnon R, Thurlow B, et al.
Leuk Lymphoma
. 2022 Mar;
64(3):722-724.
PMID: 35263204
No abstract available.